Cellectar Biosciences Stock Performance
| CLRB Stock | USD 1.57 0.01 0.63% |
The firm shows a Beta (market volatility) of 1.1, which signifies a somewhat significant risk relative to the market. Cellectar Biosciences returns are very sensitive to returns on the market. As the market goes up or down, Cellectar Biosciences is expected to follow. At this point, Cellectar Biosciences has a negative expected return of -0.49%. Please make sure to confirm Cellectar Biosciences' treynor ratio, accumulation distribution, price action indicator, as well as the relationship between the potential upside and day median price , to decide if Cellectar Biosciences performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Cellectar Biosciences has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in December 2024. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Last Split Factor 1:10 | Dividend Date 2018-07-17 | Last Split Date 2022-07-22 |
1 | Acquisition by Jarrod Longcor of 450000 shares of Cellectar Biosciences at 1.74 subject to Rule 16b-3 | 09/19/2024 |
2 | Cellectar Biosciences regains compliance with Nasdaq | 11/01/2024 |
3 | Cellectar Biosciences and SpectronRx Partner to Manufacture Novel Phospholipid Radioconjugate for the Treatment of Cancer | 11/12/2024 |
4 | Cellectar Biosciences GAAP EPS of -0.40 misses by 0.03 | 11/18/2024 |
5 | Cellectar Biosciences Reports Financial Results for Q3 2024 and Provides Corporate Update | 11/19/2024 |
6 | Cellectar Biosciences, Inc. Q3 2024 Earnings Call Transcript | 11/21/2024 |
| Begin Period Cash Flow | 19.9 M |
Cellectar |
Cellectar Biosciences Relative Risk vs. Return Landscape
If you would invest 220.00 in Cellectar Biosciences on August 28, 2024 and sell it today you would lose (63.00) from holding Cellectar Biosciences or give up 28.64% of portfolio value over 90 days. Cellectar Biosciences is currently does not generate positive expected returns and assumes 2.6226% risk (volatility on return distribution) over the 90 days horizon. In different words, 23% of stocks are less volatile than Cellectar, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Cellectar Biosciences Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Cellectar Biosciences' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Cellectar Biosciences, and traders can use it to determine the average amount a Cellectar Biosciences' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1874
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | CLRB |
Estimated Market Risk
| 2.62 actual daily | 23 77% of assets are more volatile |
Expected Return
| -0.49 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.19 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Cellectar Biosciences is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Cellectar Biosciences by adding Cellectar Biosciences to a well-diversified portfolio.
Cellectar Biosciences Fundamentals Growth
Cellectar Stock prices reflect investors' perceptions of the future prospects and financial health of Cellectar Biosciences, and Cellectar Biosciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Cellectar Stock performance.
| Return On Equity | -7.97 | ||||
| Return On Asset | -1.66 | ||||
| Current Valuation | 45.07 M | ||||
| Shares Outstanding | 41.27 M | ||||
| Price To Earning | (1.35) X | ||||
| Price To Book | 42.09 X | ||||
| EBITDA | (38.77 M) | ||||
| Net Income | (37.98 M) | ||||
| Cash And Equivalents | 24.81 M | ||||
| Cash Per Share | 4.06 X | ||||
| Total Debt | 552.98 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 4.51 X | ||||
| Book Value Per Share | (0.96) X | ||||
| Cash Flow From Operations | (32.38 M) | ||||
| Earnings Per Share | (1.41) X | ||||
| Market Capitalization | 65.21 M | ||||
| Total Asset | 12.08 M | ||||
| Retained Earnings | (217.48 M) | ||||
| Working Capital | (2.48 M) | ||||
| Current Asset | 8.14 M | ||||
| Current Liabilities | 1.39 M | ||||
About Cellectar Biosciences Performance
By analyzing Cellectar Biosciences' fundamental ratios, stakeholders can gain valuable insights into Cellectar Biosciences' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Cellectar Biosciences has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Cellectar Biosciences has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (3.15) | (2.99) | |
| Return On Capital Employed | 45.20 | 47.46 | |
| Return On Assets | (3.15) | (2.99) | |
| Return On Equity | 28.01 | 29.41 |
Things to note about Cellectar Biosciences performance evaluation
Checking the ongoing alerts about Cellectar Biosciences for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Cellectar Biosciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Cellectar Biosciences generated a negative expected return over the last 90 days | |
| Cellectar Biosciences may become a speculative penny stock | |
| Net Loss for the year was (37.98 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Cellectar Biosciences currently holds about 24.81 M in cash with (32.38 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.06, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Cellectar Biosciences has a poor financial position based on the latest SEC disclosures | |
| Latest headline from insidermonkey.com: Cellectar Biosciences, Inc. Q3 2024 Earnings Call Transcript |
- Analyzing Cellectar Biosciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Cellectar Biosciences' stock is overvalued or undervalued compared to its peers.
- Examining Cellectar Biosciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Cellectar Biosciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Cellectar Biosciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Cellectar Biosciences' stock. These opinions can provide insight into Cellectar Biosciences' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Cellectar Stock analysis
When running Cellectar Biosciences' price analysis, check to measure Cellectar Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cellectar Biosciences is operating at the current time. Most of Cellectar Biosciences' value examination focuses on studying past and present price action to predict the probability of Cellectar Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cellectar Biosciences' price. Additionally, you may evaluate how the addition of Cellectar Biosciences to your portfolios can decrease your overall portfolio volatility.
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges |